Literature DB >> 7604141

The effect of carbamazepine on the 2-hydroxylation of desipramine.

E Spina1, A Avenoso, G M Campo, A P Caputi, E Perucca.   

Abstract

The effect of carbamazepine (CBZ, 200 mg twice daily for 28 days) on the kinetics of a single oral dose of desipramine (DMI, 100 mg) was investigated in six healthy volunteers. Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01). The amount of 2-hydroxydesipramine (2-OH-DMI) excreted in urine over a 24-h period was significantly increased during CBZ intake (from 75 +/- 15 to 92 +/- 16 mumol, P < 0.01). These findings suggest that CBZ induces the 2-hydroxylation of DMI, a reaction primarily catalyzed by the polymorphic CYP2D6 isozyme. This interaction may have considerable practical significance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7604141     DOI: 10.1007/BF02246212

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

Review 1.  Molecular genetics of the debrisoquin-sparteine polymorphism.

Authors:  F J Gonzalez; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1991-09       Impact factor: 6.875

2.  Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients.

Authors:  E Leinonen; P Lillsunde; V Laukkanen; P Ylitalo
Journal:  J Clin Psychopharmacol       Date:  1991-10       Impact factor: 3.153

3.  The influence of enzyme induction on polymorphic sparteine oxidation.

Authors:  M Eichelbaum; S Mineshita; E E Ohnhaus; C Zekorn
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

4.  High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites.

Authors:  T A Sutfin; W J Jusko
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

5.  Effects of carbamazepine on plasma haloperidol levels.

Authors:  M W Jann; L Ereshefsky; S R Saklad; D R Seidel; C M Davis; N R Burch; C L Bowden
Journal:  J Clin Psychopharmacol       Date:  1985-04       Impact factor: 3.153

Review 6.  Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications.

Authors:  E Spina; A P Caputi
Journal:  Pharmacol Res       Date:  1994 Feb-Mar       Impact factor: 7.658

7.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

8.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

9.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.

Authors:  E Spina; C Birgersson; C von Bahr; O Ericsson; B Mellström; E Steiner; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

10.  The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline.

Authors:  M Jerling; L Bertilsson; F Sjöqvist
Journal:  Ther Drug Monit       Date:  1994-02       Impact factor: 3.681

View more
  6 in total

Review 1.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.

Authors:  Kari Laine; Steven De Bruyn; Harry Björklund; Juha Rouru; Jutta Hänninen; Harry Scheinin; Markku Anttila
Journal:  Eur J Clin Pharmacol       Date:  2004-01-17       Impact factor: 2.953

Review 4.  Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.

Authors:  P Glue; R P Clement
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 5.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.

Authors:  Walter Krauwinkel; James Dickinson; Marloes Schaddelee; John Meijer; Reiner Tretter; Jeroen van de Wetering; Gregory Strabach; Marcel van Gelderen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-01       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.